InflaRx Reports Q1 2020 Financial & Operating Results
May 21, 2020 07:30 ET
|
InflaRx N.V.
End of Phase II meeting with the FDA scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized...
InflaRx Reports Full Year 2019 Financial & Operating Results
April 29, 2020 08:00 ET
|
InflaRx N.V.
End of Phase 2 FDA meeting scheduled to discuss the path forward for IFX-1 in Hidradenitis SuppurativaInitial promising results reported in Pyoderma GangraenosumPart 1 of adaptive randomized trial in...
InflaRx Doses First Patient in Multicenter Randomized Clinical Trial in Severe Progressed COVID-19 Pneumonia in Europe upon Receipt of Initial Positive Human Data with InflaRx’s anti-C5a Technology
March 31, 2020 16:15 ET
|
InflaRx N.V.
InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the NetherlandsInflaRx received initial positive human...
InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Patients Suffering from Pyoderma Gangraenosum
February 26, 2020 07:30 ET
|
InflaRx N.V.
Two out of the first five patients dosed with IFX-1 achieved complete remissionDose escalation warranted by pharmacodynamic analysis and approved by relevant authorities for a total enrollment of 18...
InflaRx to Present at Upcoming SVB Leerink Global Healthcare Conference
February 19, 2020 08:00 ET
|
InflaRx N.V.
JENA, Germany, Feb. 19, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx to Present at Upcoming J.P. Morgan Annual Healthcare Conference
January 09, 2020 07:30 ET
|
InflaRx N.V.
JENA, Germany, Jan. 09, 2020 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system,...
InflaRx Reports Second Quarter 2019 Financial & Operating Results
August 14, 2019 16:05 ET
|
InflaRx N.V.
IFX-1 in Hidradenitis Suppurativa did not meet the primary endpoint; trial ongoing - multiple efficacy signals for high-dose group identifiedFirst patient treated in Pyoderma Gangraenosum phase IIa...
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
July 18, 2019 16:01 ET
|
InflaRx N.V.
IFX-1 treatment in high dose group resulted in multiple efficacy signals supporting further development of IFX-1 in HSIFX-1 suppressed C5a levels dose dependently and exhibited a favorable safety...
InflaRx Treats First Patient in Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum
June 13, 2019 09:00 ET
|
InflaRx N.V.
Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers JENA, Germany, June 13, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), an innovative...
InflaRx Announces Top-Line SHINE Phase IIb Results for IFX-1 in Hidradenitis Suppurativa
June 05, 2019 07:49 ET
|
InflaRx N.V.
IFX-1 did not demonstrate a statistically significant dose dependent effect on Hidradenitis Suppurativa Clinical Response (HiSCR) rate at week 16 as primary endpoint IFX-1 treatment achieved a maximum...